SCHEMBL23640271

SCHEMBL23640271

O=C(O)Cc1noc2ccc3c(c12)OCO3

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.37
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
AOC3 Q16853 3/20 0.35
MAPK1 P28482 1/20 0.34
POLB P06746 2/20 0.34
NPC1 O15118 1/20 0.34
AGBL2 Q5U5Z8 1/20 0.33
CDC7 O00311 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24302896 0.82 SMN1; SMN2 (0.40) SMN1; SMN2RAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL24302903 0.74 MAPT (0.55) MAPTSMN1; SMN2RAB9AALDH1A1CYP1A2
SCHEMBL30507865 0.72 KDR (0.38) ALDH1A1AOC3MAPK1CDC7
SCHEMBL11211516 0.70 MAPT (0.50) MAPTSMN1; SMN2RAB9AALDH1A1CYP1A2
SCHEMBL23640218 0.70 MAPT (0.47) MAPTSMN1; SMN2ALDH1A1KDM4ETP53
SCHEMBL31560779 0.69 AKR1B1 (0.47) MAPTSMN1; SMN2RAB9AKDM4ETP53
SCHEMBL11206996 0.69 SMN1; SMN2 (0.46) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL11205275 0.69 SMN1; SMN2 (0.60) MAPTSMN1; SMN2RAB9APOLBNPC1
SCHEMBL3402977 0.67 KDM4C (0.50) SMN1; SMN2ALDH1A1MAPK1POLBAGBL2
SCHEMBL23640288 0.67 MAPT (0.50) MAPTSMN1; SMN2KDM4EESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
EP-3848367-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 MAPT 539/4885SMN1; SMN2 2099/4885RAB9A 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.